Joshua S. Salafsky

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.